Litigation Details for Alvotech USA Inc. v. Abbvie Inc (E.D. Va. 2021)

« Back to Dashboard

Alvotech USA Inc. v. Abbvie Inc (E.D. Va. 2021)

Docket		Date Filed	2021-05-11
Court	District Court, E.D. Virginia	Date Terminated	2021-10-22
Cause	35:1 Patent Non-Infringement - Declaratory Judgment	Assigned To	Raymond Alvin Jackson
Jury Demand	Plaintiff	Referred To	Douglas E. Miller
Patents	8,420,081; 8,889,136; 8,926,975; 8,961,973; 9,085,619
Link to Docket	External link to docket

Details for Alvotech USA Inc. v. Abbvie Inc (E.D. Va. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-05-11				External link to document

Alvotech USA Inc. v. AbbVie Inc. Litigation Summary and Patent Analysis, 2:21-cv-00265

Last updated: August 9, 2026

Alvotech USA Inc. v. AbbVie Inc., No. 2:21-cv-00265, was a U.S. biosimilar patent dispute involving Alvotech’s adalimumab biosimilar candidate, AVT02, and AbbVie’s Humira franchise. The case was filed in the U.S. District Court for the Eastern District of Texas, Marshall Division. It ended through a confidential settlement rather than a trial or final ruling on patent validity or infringement. The settlement permitted U.S. commercialization of AVT02 after an agreed date in 2023, subject to FDA approval and other launch conditions.[1][2]

AVT02 was later approved by the FDA as Simlandi (adalimumab-ryvk), including an interchangeable biosimilar designation. The dispute therefore formed part of AbbVie’s broader Humira patent-exclusivity strategy and Alvotech’s effort to enter the U.S. market with a high-concentration, citrate-free adalimumab product.[3]

What was the Alvotech v. AbbVie case about?

The case concerned whether AbbVie could use its Humira patent portfolio to delay Alvotech’s U.S. launch of AVT02. Alvotech pursued declaratory and patent-related relief against AbbVie in connection with its biosimilar product and the patent-resolution process under the Biologics Price Competition and Innovation Act, or BPCIA.

The dispute involved:

Item	Detail
Case	Alvotech USA Inc. v. AbbVie Inc.
Civil action	No. 2:21-cv-00265
Court	U.S. District Court for the Eastern District of Texas
Division	Marshall Division
Plaintiff	Alvotech USA Inc.
Defendant	AbbVie Inc.
Reference product	Humira
Active ingredient	Adalimumab
Biosimilar candidate	AVT02
FDA product name	Simlandi, adalimumab-ryvk
Regulatory pathway	BPCIA section 351(k)
Disposition	Settlement and dismissal
Public merits ruling	None resolving validity or infringement

The case did not produce a judicial determination that AbbVie’s patents were valid, invalid, infringed, or not infringed. Its commercial significance came from the settlement’s effect on launch timing.

Which drug and patents were involved?

Humira contains adalimumab, a monoclonal antibody that inhibits tumor necrosis factor alpha. AbbVie developed several patent categories around the product:

1. The original adalimumab composition and antibody patents.
2. Manufacturing and cell-line patents.
3. Formulation patents, including citrate-free and high-concentration formulations.
4. Dosing and treatment-method patents.
5. Device and administration patents.
6. Pediatric and other method-of-use patents.

The earliest core Humira patents expired before the major U.S. biosimilar launches. AbbVie nevertheless accumulated a large secondary patent estate. The portfolio was intended to protect product characteristics and commercial uses after the principal molecule patents approached expiration.[4]

AVT02 targeted the commercial Humira product, including high-concentration, citrate-free adalimumab presentations. Those characteristics mattered because high-concentration and citrate-free formulations became important in the U.S. market as AbbVie transitioned patients away from the original lower-concentration product.

Were formulation patents important?

Yes. Formulation patents were central to the commercial dispute because Humira’s later-generation product differed from the original formulation in concentration and excipients. A biosimilar applicant can face separate patent allegations concerning:

• Concentration of the antibody solution.
• Citrate-free excipient systems.
• Buffer composition.
• Stability during storage.
• Prefilled syringe and autoinjector presentations.
• Injection-volume and administration characteristics.

A biosimilar may avoid some claims through formulation differences, claim construction positions, or non-infringement arguments. It may also challenge patents as obvious, anticipated, improperly broadened, or otherwise invalid. The Alvotech case settled before the court resolved those issues.

What was the procedural history of the litigation?

Alvotech filed the action in 2021 as part of its effort to establish a route to U.S. market entry for AVT02. The action was connected to the BPCIA patent framework, which requires information exchange between a biosimilar applicant and the reference-product sponsor and permits patent litigation before commercial launch.

The case did not proceed to a public trial. Alvotech and AbbVie reached a settlement under which Alvotech obtained a defined U.S. entry date for AVT02. The court then dismissed the action pursuant to the parties’ agreement.[1][2]

The public record does not disclose the settlement’s financial terms, patent-by-patent concessions, covenant language, or detailed launch conditions. The key commercial term was the agreed timing of U.S. entry.

Did the case involve a Paragraph IV challenge?

The BPCIA does not use the Hatch-Waxman Paragraph IV mechanism that applies to small-molecule drugs. AVT02 was a biologic licensed under the section 351(k) biosimilar pathway, not an ANDA product.

The functional equivalent was a biosimilar patent challenge under the BPCIA. Alvotech could contest AbbVie patents through invalidity and non-infringement positions and seek a judicial resolution before launch. References to a “Paragraph IV challenge” in connection with this case are therefore technically inaccurate.

When did Alvotech obtain the right to launch AVT02 in the United States?

The settlement allowed Alvotech to commercialize AVT02 in the United States beginning July 1, 2023, subject to FDA approval and applicable settlement conditions.[2]

The settlement date did not itself authorize marketing. Alvotech still needed FDA approval under the 351(k) pathway. The FDA approved Simlandi on February 23, 2024, as adalimumab-ryvk. The product received an interchangeable biosimilar designation, allowing pharmacy-level substitution under applicable state law and payer practices.[3]

The commercial timeline was therefore:

Date	Event
2021	Alvotech filed the patent dispute against AbbVie
2022	Alvotech and AbbVie reached a confidential settlement
July 1, 2023	Contractual U.S. entry date under the settlement
February 23, 2024	FDA approved Simlandi, adalimumab-ryvk
2024	U.S. commercialization became possible after regulatory approval

What was the Orange Book status of Humira?

Humira is a biologic, so its relevant FDA patent listings are generally associated with the Purple Book and BPCIA patent process rather than the Orange Book. The Orange Book primarily covers approved small-molecule drug products and related patents submitted under the Hatch-Waxman framework.

The absence of a conventional Orange Book listing did not reduce AbbVie’s ability to assert patent rights. AbbVie could enforce relevant patents through district-court litigation and seek remedies available under the patent laws.

The patent issues in the Alvotech case therefore included the broader Humira patent estate, not an Orange Book patent listing in the conventional ANDA sense.

How strong was AbbVie’s patent estate against Alvotech?

AbbVie’s estate was commercially strong but legally untested in this particular action. Its strength came from the number and variety of patents, the commercial importance of the high-concentration formulation, and the ability to assert different patent categories at different stages of a biosimilar launch.

Its principal advantages were:

• A large portfolio covering formulation, dosing, manufacturing, and delivery.
• Multiple potential litigation theories.
• The ability to seek launch delay through settlement negotiations.
• Significant revenue exposure for a biosimilar entrant.
• The cost and time burden associated with biologic patent litigation.

The estate also had limitations. Secondary patents generally face greater validity risk than core composition patents because they may be challenged on obviousness, written-description, enablement, anticipation, or patent-term grounds. A large portfolio does not mean every asserted claim is enforceable or infringed.

Because the case settled, no public judgment established the enforceability of the patents asserted or threatened against AVT02.

Which companies challenged AbbVie’s Humira exclusivity?

AbbVie faced challenges from several biosimilar developers, including Amgen, Samsung Bioepis, Boehringer Ingelheim, Sandoz, Pfizer, Celltrion, Coherus, Organon, Viatris and Alvotech. AbbVie entered separate settlements with many of those companies, producing staggered U.S. launch dates beginning in 2023.[4][5]

The resulting market structure reduced the likelihood of a single immediate “first generic” event. Instead, Humira faced multiple biosimilar entrants with different commercial agreements, interchangeability statuses, payer contracts and launch strategies.

Alvotech’s competitive position depended on:

• FDA approval timing.
• Interchangeability status.
• Manufacturing capacity.
• Wholesale and payer contracting.
• The commercial relationship used to distribute Simlandi in the United States.
• The ability to supply both high-concentration and citrate-free presentations.

What generic or biosimilar entry risks did the settlement create for AbbVie?

The settlement created a controlled entry risk rather than an immediate unrestricted launch risk. AbbVie preserved several years of market exclusivity after the initial Humira patent expiration period, while Alvotech secured a contractual path to market.

For AbbVie, the main risks were:

1. Price erosion from multiple adalimumab biosimilars.
2. Loss of volume to interchangeable products.
3. Payer-driven substitution.
4. Declining revenue from Humira after biosimilar contracting.
5. Competitive pressure on high-concentration and citrate-free presentations.

For Alvotech, the settlement reduced patent uncertainty but left substantial commercial risks. Entering after several established biosimilar competitors could limit pricing power and formulary access. Alvotech also faced manufacturing and supply obligations tied to a complex monoclonal-antibody product.

Did the case establish precedent for biosimilar patent litigation?

No. The action ended without a substantive opinion. It did not establish a binding rule on:

• The scope of BPCIA patent disclosures.
• Patent-dance compliance.
• Validity of Humira formulation patents.
• Infringement by AVT02.
• The enforceability of AbbVie’s method-of-use patents.
• The legal effect of settlement-based launch dates.

Its value is commercial and strategic rather than precedential. The case illustrates how a biosimilar applicant can use litigation to negotiate a defined entry date while avoiding the cost of a full patent trial.

How does Alvotech’s Humira strategy compare with other biosimilar entrants?

Alvotech pursued a high-concentration, citrate-free product profile aligned with the later-generation Humira market. That approach offered clinical and commercial compatibility with the formulation increasingly used in U.S. practice but exposed the product to formulation and device-related patent scrutiny.

The key differentiators were:

Factor	Alvotech AVT02	Other Humira biosimilars
Product	High-concentration, citrate-free adalimumab	Varies by sponsor
FDA status	Approved as Simlandi; interchangeable designation	Approval and interchangeability vary
Patent strategy	Settlement with AbbVie	Separate settlements and launch dates
Main legal exposure	Formulation, method, device and related patents	Varies by product and presentation
Market issue	Entry into a crowded biosimilar field	Contracting, price and substitution

What is the current litigation status?

The action is resolved and no longer presents an active merits dispute between Alvotech and AbbVie under the identified civil action. The case ended by settlement and dismissal. The settlement remains commercially relevant because it governed the timing of Alvotech’s U.S. entry, but it did not invalidate AbbVie’s Humira patents or create a public license covering every Humira-related patent.

Key Takeaways

• Alvotech USA Inc. v. AbbVie Inc., No. 2:21-cv-00265, was a Humira biosimilar patent dispute involving AVT02.
• The case was filed in the Eastern District of Texas and ended through settlement.
• The parties did not obtain a public merits ruling on patent validity or infringement.
• The settlement permitted U.S. entry beginning July 1, 2023, subject to FDA approval and contractual conditions.
• FDA approved AVT02 as Simlandi, adalimumab-ryvk, on February 23, 2024.
• Simlandi received an interchangeable biosimilar designation.
• The dispute involved the broader Humira patent estate, including formulation, method-of-use, manufacturing and delivery-related patents.
• Paragraph IV terminology does not technically apply because AVT02 followed the BPCIA biologics pathway.
• The case reduced Alvotech’s launch uncertainty but did not remove commercial risks from a crowded adalimumab biosimilar market.
• The settlement did not establish precedent on AbbVie’s patent validity or infringement positions.

FAQs About Alvotech v. AbbVie

What product did Alvotech seek to launch against Humira?

Alvotech sought to launch AVT02, a high-concentration, citrate-free adalimumab biosimilar later approved by the FDA as Simlandi, adalimumab-ryvk.

Was Alvotech’s product interchangeable with Humira?

The FDA approved Simlandi with an interchangeable biosimilar designation. Interchangeability supports pharmacy-level substitution subject to state law and payer requirements.

Did Alvotech win the patent case against AbbVie?

Neither party received a public merits victory. The litigation ended through settlement and dismissal.

Did AbbVie license all Humira patents to Alvotech?

The public settlement disclosures do not establish a license to every Humira-related patent. They establish a negotiated framework for Alvotech’s U.S. commercialization.

Why was the case filed in the Eastern District of Texas?

The action was filed in the Eastern District of Texas, a major venue for patent disputes. The docket does not convert the case into an ANDA action or establish that the court ruled on the underlying Humira patents.

References

1. U.S. District Court for the Eastern District of Texas. (2021-2022). Alvotech USA Inc. v. AbbVie Inc., No. 2:21-cv-00265, docket and orders.
2. Alvotech. (2022). Alvotech announces settlement agreement with AbbVie regarding AVT02 in the United States. Company press release.
3. U.S. Food and Drug Administration. (2024, February 23). FDA approves interchangeable biosimilar to Humira.
4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
5. Federal Trade Commission. (2023). Competition and patent settlements involving adalimumab biosimilars.